UCB SA
UCB SA (UCB.BR) Stock Competitors & Peer Comparison
See (UCB.BR) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UCB.BR | €264.50 | -1.23% | 50.4B | 32.94 | €8.03 | +0.45% |
| ARGX.BR | €647.20 | +0.22% | 40.1B | 38.25 | €16.92 | N/A |
| TUB.BR | €219.50 | +0.69% | 9.8B | 104.52 | €2.10 | +0.41% |
| ABVX.PA | €101.40 | -0.59% | 8B | -20.99 | -€4.83 | N/A |
| GLPG.AS | €25.60 | -1.31% | 1.7B | 5.28 | €4.85 | N/A |
| NANO.PA | €27.40 | -5.35% | 1.3B | -54.80 | -€0.50 | N/A |
| PHARM.AS | €1.43 | -1.78% | 998.4M | -143.30 | -€0.01 | N/A |
| MEDCL.PA | €23.10 | -0.69% | 829.4M | -37.87 | -€0.61 | N/A |
| IVA.PA | €4.72 | +3.17% | 656.4M | -2.48 | -€1.90 | N/A |
| GTBP.PA | €280.50 | +0.00% | 626.7M | -4.10 | -€68.39 | N/A |
Stock Comparison
UCB.BR vs ARGX.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ARGX.BR has a market cap of 40.1B. Regarding current trading prices, UCB.BR is priced at €264.50, while ARGX.BR trades at €647.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ARGX.BR's P/E ratio is 38.25. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ARGX.BR's ROE of +0.17%. Regarding short-term risk, UCB.BR is less volatile compared to ARGX.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ARGX.BR's competition here
UCB.BR vs TUB.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, TUB.BR has a market cap of 9.8B. Regarding current trading prices, UCB.BR is priced at €264.50, while TUB.BR trades at €219.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas TUB.BR's P/E ratio is 104.52. In terms of profitability, UCB.BR's ROE is +0.15%, compared to TUB.BR's ROE of +0.05%. Regarding short-term risk, UCB.BR is less volatile compared to TUB.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check TUB.BR's competition here
UCB.BR vs ABVX.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ABVX.PA has a market cap of 8B. Regarding current trading prices, UCB.BR is priced at €264.50, while ABVX.PA trades at €101.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ABVX.PA's P/E ratio is -20.99. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ABVX.PA's ROE of -1.65%. Regarding short-term risk, UCB.BR is less volatile compared to ABVX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ABVX.PA's competition here
UCB.BR vs GLPG.AS Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, GLPG.AS has a market cap of 1.7B. Regarding current trading prices, UCB.BR is priced at €264.50, while GLPG.AS trades at €25.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas GLPG.AS's P/E ratio is 5.28. In terms of profitability, UCB.BR's ROE is +0.15%, compared to GLPG.AS's ROE of +0.11%. Regarding short-term risk, UCB.BR is more volatile compared to GLPG.AS. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check GLPG.AS's competition here
UCB.BR vs NANO.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, NANO.PA has a market cap of 1.3B. Regarding current trading prices, UCB.BR is priced at €264.50, while NANO.PA trades at €27.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas NANO.PA's P/E ratio is -54.80. In terms of profitability, UCB.BR's ROE is +0.15%, compared to NANO.PA's ROE of +0.77%. Regarding short-term risk, UCB.BR is less volatile compared to NANO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check NANO.PA's competition here
UCB.BR vs PHARM.AS Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, PHARM.AS has a market cap of 998.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while PHARM.AS trades at €1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas PHARM.AS's P/E ratio is -143.30. In terms of profitability, UCB.BR's ROE is +0.15%, compared to PHARM.AS's ROE of +0.01%. Regarding short-term risk, UCB.BR is more volatile compared to PHARM.AS. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check PHARM.AS's competition here
UCB.BR vs MEDCL.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, MEDCL.PA has a market cap of 829.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while MEDCL.PA trades at €23.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas MEDCL.PA's P/E ratio is -37.87. In terms of profitability, UCB.BR's ROE is +0.15%, compared to MEDCL.PA's ROE of +0.85%. Regarding short-term risk, UCB.BR is more volatile compared to MEDCL.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check MEDCL.PA's competition here
UCB.BR vs IVA.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, IVA.PA has a market cap of 656.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while IVA.PA trades at €4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas IVA.PA's P/E ratio is -2.48. In terms of profitability, UCB.BR's ROE is +0.15%, compared to IVA.PA's ROE of +5.36%. Regarding short-term risk, UCB.BR is less volatile compared to IVA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check IVA.PA's competition here
UCB.BR vs GTBP.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, GTBP.PA has a market cap of 626.7M. Regarding current trading prices, UCB.BR is priced at €264.50, while GTBP.PA trades at €280.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas GTBP.PA's P/E ratio is -4.10. In terms of profitability, UCB.BR's ROE is +0.15%, compared to GTBP.PA's ROE of -8.81%. Regarding short-term risk, UCB.BR is less volatile compared to GTBP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check GTBP.PA's competition here
UCB.BR vs DBV.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, DBV.PA has a market cap of 614.7M. Regarding current trading prices, UCB.BR is priced at €264.50, while DBV.PA trades at €3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas DBV.PA's P/E ratio is -3.99. In terms of profitability, UCB.BR's ROE is +0.15%, compared to DBV.PA's ROE of -1.89%. Regarding short-term risk, UCB.BR is less volatile compared to DBV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check DBV.PA's competition here
UCB.BR vs VLA.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, VLA.PA has a market cap of 466.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while VLA.PA trades at €2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas VLA.PA's P/E ratio is -3.99. In terms of profitability, UCB.BR's ROE is +0.15%, compared to VLA.PA's ROE of -0.75%. Regarding short-term risk, UCB.BR is less volatile compared to VLA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check VLA.PA's competition here
UCB.BR vs GNFT.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, GNFT.PA has a market cap of 430.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while GNFT.PA trades at €8.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas GNFT.PA's P/E ratio is -11.06. In terms of profitability, UCB.BR's ROE is +0.15%, compared to GNFT.PA's ROE of -0.64%. Regarding short-term risk, UCB.BR is less volatile compared to GNFT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check GNFT.PA's competition here
UCB.BR vs ALCLS.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALCLS.PA has a market cap of 224.6M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALCLS.PA trades at €3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALCLS.PA's P/E ratio is -5.35. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALCLS.PA's ROE of -0.70%. Regarding short-term risk, UCB.BR is less volatile compared to ALCLS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALCLS.PA's competition here
UCB.BR vs ORY.MC Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ORY.MC has a market cap of 220M. Regarding current trading prices, UCB.BR is priced at €264.50, while ORY.MC trades at €2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ORY.MC's P/E ratio is -93.00. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ORY.MC's ROE of -0.03%. Regarding short-term risk, UCB.BR is more volatile compared to ORY.MC. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check ORY.MC's competition here
UCB.BR vs ONWD.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ONWD.BR has a market cap of 144.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while ONWD.BR trades at €3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ONWD.BR's P/E ratio is -3.59. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ONWD.BR's ROE of -0.93%. Regarding short-term risk, UCB.BR is less volatile compared to ONWD.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ONWD.BR's competition here
UCB.BR vs HYL.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, HYL.BR has a market cap of 135.8M. Regarding current trading prices, UCB.BR is priced at €264.50, while HYL.BR trades at €4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas HYL.BR's P/E ratio is -20.21. In terms of profitability, UCB.BR's ROE is +0.15%, compared to HYL.BR's ROE of -0.17%. Regarding short-term risk, UCB.BR is less volatile compared to HYL.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check HYL.BR's competition here
UCB.BR vs ABNX.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ABNX.PA has a market cap of 130.3M. Regarding current trading prices, UCB.BR is priced at €264.50, while ABNX.PA trades at €3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ABNX.PA's P/E ratio is -28.42. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ABNX.PA's ROE of -1.15%. Regarding short-term risk, UCB.BR is less volatile compared to ABNX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ABNX.PA's competition here
UCB.BR vs ALSEN.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALSEN.PA has a market cap of 127.9M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALSEN.PA trades at €0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALSEN.PA's P/E ratio is -4.18. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALSEN.PA's ROE of -0.58%. Regarding short-term risk, UCB.BR is less volatile compared to ALSEN.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALSEN.PA's competition here
UCB.BR vs IPH.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, IPH.PA has a market cap of 108.9M. Regarding current trading prices, UCB.BR is priced at €264.50, while IPH.PA trades at €1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas IPH.PA's P/E ratio is -2.11. In terms of profitability, UCB.BR's ROE is +0.15%, compared to IPH.PA's ROE of +5.94%. Regarding short-term risk, UCB.BR is less volatile compared to IPH.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check IPH.PA's competition here
UCB.BR vs TNG.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, TNG.PA has a market cap of 106.7M. Regarding current trading prices, UCB.BR is priced at €264.50, while TNG.PA trades at €0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas TNG.PA's P/E ratio is -2.85. In terms of profitability, UCB.BR's ROE is +0.15%, compared to TNG.PA's ROE of -0.64%. Regarding short-term risk, UCB.BR is less volatile compared to TNG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check TNG.PA's competition here
UCB.BR vs ADOC.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ADOC.PA has a market cap of 90.8M. Regarding current trading prices, UCB.BR is priced at €264.50, while ADOC.PA trades at €4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ADOC.PA's P/E ratio is -4.94. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ADOC.PA's ROE of +5.24%. Regarding short-term risk, UCB.BR is less volatile compared to ADOC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ADOC.PA's competition here
UCB.BR vs MAAT.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, MAAT.PA has a market cap of 86.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while MAAT.PA trades at €5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas MAAT.PA's P/E ratio is -2.66. In terms of profitability, UCB.BR's ROE is +0.15%, compared to MAAT.PA's ROE of -3.34%. Regarding short-term risk, UCB.BR is less volatile compared to MAAT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check MAAT.PA's competition here
UCB.BR vs OSE.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, OSE.PA has a market cap of 73.8M. Regarding current trading prices, UCB.BR is priced at €264.50, while OSE.PA trades at €3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas OSE.PA's P/E ratio is -13.71. In terms of profitability, UCB.BR's ROE is +0.15%, compared to OSE.PA's ROE of -0.61%. Regarding short-term risk, UCB.BR is less volatile compared to OSE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check OSE.PA's competition here
UCB.BR vs ERYP.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ERYP.PA has a market cap of 48.7M. Regarding current trading prices, UCB.BR is priced at €264.50, while ERYP.PA trades at €0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ERYP.PA's P/E ratio is -80.10. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ERYP.PA's ROE of -0.96%. Regarding short-term risk, UCB.BR is less volatile compared to ERYP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ERYP.PA's competition here
UCB.BR vs ALVIO.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALVIO.PA has a market cap of 42.8M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALVIO.PA trades at €0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALVIO.PA's P/E ratio is -1.36. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALVIO.PA's ROE of +1.46%. Regarding short-term risk, UCB.BR is less volatile compared to ALVIO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALVIO.PA's competition here
UCB.BR vs VVY.AS Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, VVY.AS has a market cap of 39.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while VVY.AS trades at €1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas VVY.AS's P/E ratio is -2.77. In terms of profitability, UCB.BR's ROE is +0.15%, compared to VVY.AS's ROE of -2.26%. Regarding short-term risk, UCB.BR is more volatile compared to VVY.AS. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check VVY.AS's competition here
UCB.BR vs COX.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, COX.PA has a market cap of 29M. Regarding current trading prices, UCB.BR is priced at €264.50, while COX.PA trades at €0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas COX.PA's P/E ratio is -0.46. In terms of profitability, UCB.BR's ROE is +0.15%, compared to COX.PA's ROE of -0.43%. Regarding short-term risk, UCB.BR is less volatile compared to COX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check COX.PA's competition here
UCB.BR vs ALVAL.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALVAL.PA has a market cap of 25.3M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALVAL.PA trades at €1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALVAL.PA's P/E ratio is -2.28. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALVAL.PA's ROE of -1.09%. Regarding short-term risk, UCB.BR is less volatile compared to ALVAL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALVAL.PA's competition here
UCB.BR vs FALG.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, FALG.PA has a market cap of 24M. Regarding current trading prices, UCB.BR is priced at €264.50, while FALG.PA trades at €0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas FALG.PA's P/E ratio is -2.33. In terms of profitability, UCB.BR's ROE is +0.15%, compared to FALG.PA's ROE of -0.39%. Regarding short-term risk, UCB.BR is less volatile compared to FALG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check FALG.PA's competition here
UCB.BR vs DMSIM.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, DMSIM.BR has a market cap of 23.1M. Regarding current trading prices, UCB.BR is priced at €264.50, while DMSIM.BR trades at €0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas DMSIM.BR's P/E ratio is 0.09. In terms of profitability, UCB.BR's ROE is +0.15%, compared to DMSIM.BR's ROE of -0.57%. Regarding short-term risk, UCB.BR is less volatile compared to DMSIM.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check DMSIM.BR's competition here
UCB.BR vs ALGEN.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALGEN.PA has a market cap of 22.7M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALGEN.PA trades at €2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALGEN.PA's P/E ratio is 13.83. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALGEN.PA's ROE of +0.07%. Regarding short-term risk, UCB.BR is more volatile compared to ALGEN.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check ALGEN.PA's competition here
UCB.BR vs ALDVI.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALDVI.PA has a market cap of 21.7M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALDVI.PA trades at €1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALDVI.PA's P/E ratio is -1.88. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALDVI.PA's ROE of +0.44%. Regarding short-term risk, UCB.BR is more volatile compared to ALDVI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check ALDVI.PA's competition here
UCB.BR vs AELIS.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, AELIS.PA has a market cap of 17.7M. Regarding current trading prices, UCB.BR is priced at €264.50, while AELIS.PA trades at €1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas AELIS.PA's P/E ratio is -2.17. In terms of profitability, UCB.BR's ROE is +0.15%, compared to AELIS.PA's ROE of -1.01%. Regarding short-term risk, UCB.BR is more volatile compared to AELIS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check AELIS.PA's competition here
UCB.BR vs ALPHE.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALPHE.PA has a market cap of 15.8M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALPHE.PA trades at €2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALPHE.PA's P/E ratio is -2.67. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALPHE.PA's ROE of -0.64%. Regarding short-term risk, UCB.BR is more volatile compared to ALPHE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check ALPHE.PA's competition here
UCB.BR vs SIGHT.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, SIGHT.PA has a market cap of 15.3M. Regarding current trading prices, UCB.BR is priced at €264.50, while SIGHT.PA trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas SIGHT.PA's P/E ratio is -0.68. In terms of profitability, UCB.BR's ROE is +0.15%, compared to SIGHT.PA's ROE of +0.42%. Regarding short-term risk, UCB.BR is less volatile compared to SIGHT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check SIGHT.PA's competition here
UCB.BR vs POXEL.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, POXEL.PA has a market cap of 15.1M. Regarding current trading prices, UCB.BR is priced at €264.50, while POXEL.PA trades at €0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas POXEL.PA's P/E ratio is -1.08. In terms of profitability, UCB.BR's ROE is +0.15%, compared to POXEL.PA's ROE of +0.23%. Regarding short-term risk, UCB.BR is less volatile compared to POXEL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check POXEL.PA's competition here
UCB.BR vs CYAD.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, CYAD.BR has a market cap of 14.3M. Regarding current trading prices, UCB.BR is priced at €264.50, while CYAD.BR trades at €0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas CYAD.BR's P/E ratio is -0.22. In terms of profitability, UCB.BR's ROE is +0.15%, compared to CYAD.BR's ROE of +0.67%. Regarding short-term risk, UCB.BR is less volatile compared to CYAD.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check CYAD.BR's competition here
UCB.BR vs ALNFL.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALNFL.PA has a market cap of 13.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALNFL.PA trades at €1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALNFL.PA's P/E ratio is -3.79. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALNFL.PA's ROE of -2.25%. Regarding short-term risk, UCB.BR is less volatile compared to ALNFL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALNFL.PA's competition here
UCB.BR vs BAI.AS Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, BAI.AS has a market cap of 11.2M. Regarding current trading prices, UCB.BR is priced at €264.50, while BAI.AS trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas BAI.AS's P/E ratio is -0.13. In terms of profitability, UCB.BR's ROE is +0.15%, compared to BAI.AS's ROE of -0.51%. Regarding short-term risk, UCB.BR is less volatile compared to BAI.AS. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check BAI.AS's competition here
UCB.BR vs ALVET.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALVET.PA has a market cap of 10M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALVET.PA trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALVET.PA's P/E ratio is -0.17. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALVET.PA's ROE of -0.23%. Regarding short-term risk, UCB.BR is less volatile compared to ALVET.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALVET.PA's competition here
UCB.BR vs APM.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, APM.PA has a market cap of 8.8M. Regarding current trading prices, UCB.BR is priced at €264.50, while APM.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas APM.PA's P/E ratio is -0.71. In terms of profitability, UCB.BR's ROE is +0.15%, compared to APM.PA's ROE of -0.14%. Regarding short-term risk, UCB.BR is less volatile compared to APM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check APM.PA's competition here
UCB.BR vs ALPAT.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALPAT.PA has a market cap of 8.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALPAT.PA trades at €7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALPAT.PA's P/E ratio is 9.01. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALPAT.PA's ROE of +0.11%. Regarding short-term risk, UCB.BR is less volatile compared to ALPAT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALPAT.PA's competition here
UCB.BR vs ALTME.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALTME.PA has a market cap of 6.7M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALTME.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALTME.PA's P/E ratio is -1.42. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALTME.PA's ROE of -8.77%. Regarding short-term risk, UCB.BR is less volatile compared to ALTME.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALTME.PA's competition here
UCB.BR vs ALQGC.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALQGC.PA has a market cap of 5M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALQGC.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALQGC.PA's P/E ratio is -0.09. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALQGC.PA's ROE of +8.81%. Regarding short-term risk, UCB.BR is less volatile compared to ALQGC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALQGC.PA's competition here
UCB.BR vs LYS.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, LYS.PA has a market cap of 4.9M. Regarding current trading prices, UCB.BR is priced at €264.50, while LYS.PA trades at €0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas LYS.PA's P/E ratio is -0.64. In terms of profitability, UCB.BR's ROE is +0.15%, compared to LYS.PA's ROE of -11.30%. Regarding short-term risk, UCB.BR is more volatile compared to LYS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check LYS.PA's competition here
UCB.BR vs ALHYG.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALHYG.PA has a market cap of 3.9M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALHYG.PA trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALHYG.PA's P/E ratio is -0.26. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALHYG.PA's ROE of -6.80%. Regarding short-term risk, UCB.BR is less volatile compared to ALHYG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALHYG.PA's competition here
UCB.BR vs ALACT.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALACT.PA has a market cap of 3.9M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALACT.PA trades at €0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALACT.PA's P/E ratio is -0.22. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALACT.PA's ROE of +4.93%. Regarding short-term risk, UCB.BR is more volatile compared to ALACT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check ALACT.PA's competition here
UCB.BR vs ALMDP.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALMDP.PA has a market cap of 1.8M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALMDP.PA trades at €0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALMDP.PA's P/E ratio is -0.59. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALMDP.PA's ROE of +1.42%. Regarding short-term risk, UCB.BR is less volatile compared to ALMDP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALMDP.PA's competition here
UCB.BR vs BIOS.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, BIOS.BR has a market cap of 1.4M. Regarding current trading prices, UCB.BR is priced at €264.50, while BIOS.BR trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas BIOS.BR's P/E ratio is -0.11. In terms of profitability, UCB.BR's ROE is +0.15%, compared to BIOS.BR's ROE of -1.64%. Regarding short-term risk, UCB.BR is less volatile compared to BIOS.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check BIOS.BR's competition here
UCB.BR vs ALINT.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALINT.PA has a market cap of 1.2M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALINT.PA trades at €0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALINT.PA's P/E ratio is -4.70. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALINT.PA's ROE of -1.48%. Regarding short-term risk, UCB.BR is less volatile compared to ALINT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALINT.PA's competition here
UCB.BR vs ALDEI.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALDEI.PA has a market cap of 1.1M. Regarding current trading prices, UCB.BR is priced at €264.50, while ALDEI.PA trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALDEI.PA's P/E ratio is -0.11. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALDEI.PA's ROE of +0.61%. Regarding short-term risk, UCB.BR is less volatile compared to ALDEI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALDEI.PA's competition here
UCB.BR vs GNRO.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, GNRO.PA has a market cap of 908.2K. Regarding current trading prices, UCB.BR is priced at €264.50, while GNRO.PA trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas GNRO.PA's P/E ratio is -0.05. In terms of profitability, UCB.BR's ROE is +0.15%, compared to GNRO.PA's ROE of +2.40%. Regarding short-term risk, UCB.BR is less volatile compared to GNRO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check GNRO.PA's competition here
UCB.BR vs OVXA.IR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, OVXA.IR has a market cap of 856.4K. Regarding current trading prices, UCB.BR is priced at €264.50, while OVXA.IR trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas OVXA.IR's P/E ratio is -0.21. In terms of profitability, UCB.BR's ROE is +0.15%, compared to OVXA.IR's ROE of -0.93%. Regarding short-term risk, UCB.BR is more volatile compared to OVXA.IR. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check OVXA.IR's competition here
UCB.BR vs ALBPS.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALBPS.PA has a market cap of 397.2K. Regarding current trading prices, UCB.BR is priced at €264.50, while ALBPS.PA trades at €0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALBPS.PA's P/E ratio is -0.05. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALBPS.PA's ROE of +0.92%. Regarding short-term risk, UCB.BR is less volatile compared to ALBPS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALBPS.PA's competition here
UCB.BR vs OXUR.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, OXUR.BR has a market cap of 350.5K. Regarding current trading prices, UCB.BR is priced at €264.50, while OXUR.BR trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas OXUR.BR's P/E ratio is N/A. In terms of profitability, UCB.BR's ROE is +0.15%, compared to OXUR.BR's ROE of -0.17%. Regarding short-term risk, UCB.BR is less volatile compared to OXUR.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check OXUR.BR's competition here
UCB.BR vs ALPHA.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALPHA.PA has a market cap of 1.2K. Regarding current trading prices, UCB.BR is priced at €264.50, while ALPHA.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALPHA.PA's P/E ratio is -0.00. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALPHA.PA's ROE of +0.83%. Regarding short-term risk, UCB.BR is less volatile compared to ALPHA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALPHA.PA's competition here
UCB.BR vs ALNEV.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALNEV.PA has a market cap of 238. Regarding current trading prices, UCB.BR is priced at €264.50, while ALNEV.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALNEV.PA's P/E ratio is N/A. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALNEV.PA's ROE of -1.06%. Regarding short-term risk, UCB.BR is less volatile compared to ALNEV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALNEV.PA's competition here
UCB.BR vs ORPH.IR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ORPH.IR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while ORPH.IR trades at €0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ORPH.IR's P/E ratio is N/A. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ORPH.IR's ROE of +0.27%. Regarding short-term risk, UCB.BR is more volatile compared to ORPH.IR. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check ORPH.IR's competition here
UCB.BR vs BOTHE.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, BOTHE.BR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while BOTHE.BR trades at €0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas BOTHE.BR's P/E ratio is -0.38. In terms of profitability, UCB.BR's ROE is +0.15%, compared to BOTHE.BR's ROE of +2.97%. Regarding short-term risk, UCB.BR is less volatile compared to BOTHE.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check BOTHE.BR's competition here
UCB.BR vs GKTX.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, GKTX.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while GKTX.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas GKTX.PA's P/E ratio is -2.56. In terms of profitability, UCB.BR's ROE is +0.15%, compared to GKTX.PA's ROE of -2.26%. Regarding short-term risk, UCB.BR is more volatile compared to GKTX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check GKTX.PA's competition here
UCB.BR vs ADVIC.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ADVIC.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while ADVIC.PA trades at €6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ADVIC.PA's P/E ratio is -3.67. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ADVIC.PA's ROE of +0.44%. Regarding short-term risk, UCB.BR is less volatile compared to ADVIC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ADVIC.PA's competition here
UCB.BR vs ACPH.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ACPH.BR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while ACPH.BR trades at €0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ACPH.BR's P/E ratio is -1.40. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ACPH.BR's ROE of -1.55%. Regarding short-term risk, UCB.BR is more volatile compared to ACPH.BR. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check ACPH.BR's competition here
UCB.BR vs VLAP.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, VLAP.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while VLAP.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas VLAP.PA's P/E ratio is -0.10. In terms of profitability, UCB.BR's ROE is +0.15%, compared to VLAP.PA's ROE of -0.75%. Regarding short-term risk, UCB.BR is less volatile compared to VLAP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check VLAP.PA's competition here
UCB.BR vs ALIMM.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALIMM.BR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while ALIMM.BR trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALIMM.BR's P/E ratio is -2.23. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALIMM.BR's ROE of -0.39%. Regarding short-term risk, UCB.BR is less volatile compared to ALIMM.BR. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALIMM.BR's competition here
UCB.BR vs GLPG.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, GLPG.BR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while GLPG.BR trades at €15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas GLPG.BR's P/E ratio is N/A. In terms of profitability, UCB.BR's ROE is +0.15%, compared to GLPG.BR's ROE of -0.10%. Regarding short-term risk, UCB.BR is more volatile compared to GLPG.BR. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check GLPG.BR's competition here
UCB.BR vs ASIT.BR Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ASIT.BR has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while ASIT.BR trades at €0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ASIT.BR's P/E ratio is -32.71. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ASIT.BR's ROE of +0.38%. Regarding short-term risk, UCB.BR is more volatile compared to ASIT.BR. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check ASIT.BR's competition here
UCB.BR vs ALNOX.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALNOX.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while ALNOX.PA trades at €0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALNOX.PA's P/E ratio is -0.19. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALNOX.PA's ROE of -2.36%. Regarding short-term risk, UCB.BR is less volatile compared to ALNOX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for UCB.BR.Check ALNOX.PA's competition here
UCB.BR vs ALONC.PA Comparison April 2026
UCB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UCB.BR stands at 50.4B. In comparison, ALONC.PA has a market cap of 0. Regarding current trading prices, UCB.BR is priced at €264.50, while ALONC.PA trades at €14.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UCB.BR currently has a P/E ratio of 32.94, whereas ALONC.PA's P/E ratio is 63.25. In terms of profitability, UCB.BR's ROE is +0.15%, compared to ALONC.PA's ROE of -0.09%. Regarding short-term risk, UCB.BR is more volatile compared to ALONC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for UCB.BR.Check ALONC.PA's competition here